Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Edesa Biotech

Edesa Biotech to Present at ARDS Drug Development Summit
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Appoints Strategy Expert to Board of Directors
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Edesa Biotech
Via AccessWire
Tickers EDSA
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech to Join Ontario Bioscience Panel Discussion
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech Reports Fiscal Year 2021 Results
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Tickers EDSA
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Extends COVID-19 Clinical Study to Poland
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Extends Dermatitis Study to Canada
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Reports Favorable Review of COVID-19 Study
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech to Attend BIO Digital 2021
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech to Join Panel Discussion at Industry Event
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers EDSA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.